Xilio Therapeutics (XLO) AI Stock Analysis

• Market Cap: $36.14M
• Dividend Yield: N/A
• Average Volume (3M): 753.71K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.09
• Revenue Growth: N/A
• EPS Growth: 53.92%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 51,782,272
• 10 Day Avg. Volume: 453,420
• 30 Day Avg. Volume: 753,706
• PEG Ratio: -0.05
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.95
• Enterprise Value/Market Cap: -0.74
• Enterprise Value/Revenue: -0.94
• Enterprise Value/Gross Profit: -2.89
• Enterprise Value/Ebitda: 0.11
• 1Y Price Target: $5.00
• Price Target Upside: 614.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: ―

Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company's current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company's current unprofitability.

Positive Factors

Clinical Data

The vilastobart combination therapy also demonstrates a better safety and tolerability profile compared to competing therapies.

Partnerships

The collaboration agreement with AbbVie further validates Xilio's capabilities and notably extends the cash runway.

Pipeline Development

Xilio plans to nominate multiple development candidates for its ATACR and SEECR platforms over the next few years, indicating a strong pipeline.

Negative Factors

Clinical Trial Outcomes

XTX-202 was being tested in a Phase I/II trial with expansion cohorts in melanoma/RCC. However, the monotherapy program was ultimately discontinued due to modest efficacy.

Financials

Ended 4Q24 with ~$55M in cash combined with $52M in upfront payments from collaboration with Abbvie expected to support operations into 1Q26.

Partnership Challenges

Management remains hopeful a partner can be identified for further TCE nominations.

Xilio Therapeutics Business Overview & Revenue Model

Company Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Xilio Therapeutics makes money primarily through the development and potential commercialization of its proprietary cancer therapies. The company invests in research and development to create innovative tumor-selective treatments, which it aims to bring to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams may include upfront payments, milestone payments, and royalties from licensing agreements, as well as eventual product sales pending successful clinical trials and regulatory approvals. Additionally, partnerships with other biotech or pharmaceutical firms can provide funding and resources to advance the development of its therapeutic candidates.

Xilio Therapeutics Financial Statement Overview

Summary

Xilio Therapeutics shows initial signs of revenue generation, but it faces ongoing challenges with profitability and cash flow. The company's financial stability is moderate, with potential risks due to high liabilities and negative equity trends. Continued focus on improving operational efficiency and cash flow is essential for long-term sustainability.

Income Statement

Xilio Therapeutics shows a recent improvement in revenue, achieving $6.34M in 2024, up from zero in previous years. However, the company continues to operate at a loss, with negative EBIT and EBITDA margins and no net income, indicating a challenging profitability scenario.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio due to its high equity levels, but its equity has been decreasing over time. The equity ratio is moderate, showing some financial stability. High liabilities relative to assets pose a risk.

Cash Flow

Free cash flow remains negative, but there was a significant cash inflow from financing activities in 2024. Operating cash flow to net income is not applicable due to the absence of net income, indicating cash flow challenges despite recent revenue.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.27M	6.34M	0.00	0.00	0.00	0.00
Gross Profit	9.27M	6.34M	-1.90M	-1.85M	-1.50M	-1.06M
EBITDA	-55.26M	-58.00M	-73.80M	-85.58M	-73.70M	-53.50M
Net Income	-54.30M	-58.24M	-76.40M	-87.30M	-74.30M	-55.22M
Balance Sheet
Total Assets	103.72M	71.08M	60.93M	139.16M	218.06M	36.32M
Cash, Cash Equivalents and Short-Term Investments	89.07M	55.29M	44.70M	120.39M	198.05M	19.24M
Total Debt	7.86M	8.14M	11.46M	19.94M	20.54M	21.22M
Total Liabilities	93.02M	53.48M	24.10M	33.52M	32.63M	119.60M
Stockholders Equity	10.70M	17.60M	36.83M	105.65M	185.43M	-83.29M
Cash Flow
Free Cash Flow	21.04M	-18.41M	-69.11K	-77.59M	-81.85M	-38.28M
Operating Cash Flow	21.10M	-18.38M	-68.62M	-75.72M	-80.75M	-36.09M
Investing Cash Flow	-58.00K	-36.00K	-486.00K	-1.87M	-1.10M	-2.19M
Financing Cash Flow	33.07M	29.20M	-6.55M	-69.00K	260.67M	10.03M

Xilio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XLO, the sentiment is Negative. The current price of 0.7 is above the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.76, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.85 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XLO.

Xilio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XLO	54 Neutral	$36.14M	―	-297.84%	―	―	53.92%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
CNTB	49 Neutral	$64.72M	―	-58.89%	―	―	―
LTRN	45 Neutral	$35.05M	―	-75.66%	―	―	-31.16%
XFOR	44 Neutral	$10.94M	0.84	121.75%	―	―	―
OKYO	38 Underperform	$108.90M	―	0.00%	―	―	―
FBRX	36 Underperform	$169.04M	―	-130.27%	―	―	43.64%

Xilio Therapeutics Corporate Events

Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion

On February 10, 2025, Xilio Therapeutics announced a collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies. The agreement includes an upfront payment of $52 million and potential contingent payments up to $2.1 billion. AbbVie will leverage its oncology expertise alongside Xilio’s proprietary technology to advance masked T cell engagers and other immunotherapies. This collaboration positions Xilio to accelerate its technology’s expansion into next-generation therapies, potentially enhancing its market presence and providing significant financial benefits.